Valuation

CRSPCRISPR Therapeutics AG

StockNasdaqSwitzerlandHealth careEU retail investors: available

+3.1% today · −11.6% over a year

1/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 6% of the instruments we score

Quality, Stability: among the weakest; priced higher than most peers. No dividend.

CRISPR Therapeutics AG (CRSP) valuation against sector peers: P/B 2.9, free-cash-flow yield −7.8%, P/S 192.9.

Ratios vs sector

Medians of Health care companies in the same region (stocks and REITs).

Lower P/E, P/B, P/S and EV/EBIT mean cheaper; higher yields, returns and margins mean more for the price. Negative multiples (losses) are left out of the medians.
MetricCRSPSector medianvs median
P/E—25.5 · n=26—
P/B2.93.6 · n=4518% below
P/S192.94.6 · n=404,072% above
EV/EBIT—22.5 · n=28—
Free-cash-flow yield−7.8%3.7% · n=40311% below
Dividend yield0.00%0.20% · n=99100% below
Return on equity−25.6%5.2% · n=56591% below
Return on invested capital−26.1%6.5% · n=47502% below
Gross margin—70.2% · n=39—
Net debt / EBITDA—2.08 · n=25—

Value factor: 6 of 100 within the peer group. Full score breakdown →

Sector peers

The largest companies of the same sector and region.

NVSNovartis AG22.26.718.65.7%2.4%10/10
NOVNNovartis AG22.26.718.65.7%2.8%10/10
AZNAstraZeneca plc28.35.922.84.1%1.7%6/10
AZNAstraZeneca PLC28.35.922.84.1%1.2%6/10
NVONovo Nordisk A/S11.76.210.24.9%4.6%7/10
SNYSanofi13.21.417.97.0%4.5%7/10
SANSanofi SA13.11.417.87.1%4.9%9/10
GSKGSK plc14.35.011.67.8%3.6%10/10
TEVATeva Pharmaceutical Industries Limited98.36.243.52.5%0.0%6/10
ALCAlcon37.31.729.24.7%0.4%4/10

Fiscal-year history

From annual SEC filings; each bar is a fiscal year, labelled by the year it ended.

Filings: U.S. SEC EDGAR · ratios computed by AI-Stock Invest from public filings and end-of-day prices · latest period 30 Sep 2026 · filed 02 Nov 2026